• Gap19: Mapping Cx43 Hemichannel Signaling

  2026-08-13

  Gap19 is a selective connexin 43 hemichannel blocker for separating hemichannel signaling from gap junction communication. This article integrates astrocyte, macrophage, and cerebral ischemia evidence into a practical framework for mechanistic assay design.

• LGK-974: A Practical PORCN Inhibitor Workflow

  2026-08-13

  Learn how to use LGK-974 to suppress secreted Wnt signaling in mechanistic cell assays, pancreatic cancer models, and translational workflows. The guide emphasizes dose planning, pathway-specific readouts, model selection, and troubleshooting for reproducible PORCN inhibition.

• Weight Loss Restores Intestinal Stretch Satiety

  2026-08-12

  A 2025 Molecular Metabolism study shows that intestinal stretch suppresses feeding and improves oral glucose tolerance through mechanisms that do not require classical GLP-1 signaling or vagal intestinal mechanosensation. Obesity weakens this response, whereas dietary and surgical weight loss restore it and increase neuronal activation in the nucleus of the solitary tract.

• Cirsium setidens and Doxorubicin Cardiotoxicity

  2026-08-12

  The reference study shows that a hydroethanolic extract of Cirsium setidens protects cardiomyocytes from doxorubicin-induced injury by restoring AMPK–PGC-1α–NRF1-linked mitochondrial antioxidant defenses. Its cross-model design is especially important because the extract reduced cardiac injury while preserving doxorubicin-associated apoptosis in breast cancer cells, supporting further preclinical investigation without implying clinical efficacy.

• Reversine Workflows for Aurora Kinase Studies

  2026-08-11

  Reversine provides a practical way to perturb Aurora kinase signaling, mitotic checkpoint control, and tumor-cell survival in controlled research assays. This guide combines dose-planning, apoptosis and cell-cycle readouts, high-content imaging concepts, and troubleshooting for cancer biology workflows.

• 4-Hydroxytamoxifen: Protocol and QC Guide

  2026-08-10

  4-Hydroxytamoxifen (SKU B6167) provides a DMSO-compatible estrogen receptor modulator for controlled receptor, cancer-cell, apoptosis, and cardiac myocyte workflows. It should not be selected for protocols requiring aqueous or ethanol solubility, and solution stability should not be assumed during long-term storage.

• Letrozole: An Assay-Centered Research Guide

  2026-08-09

  Letrozole is a reversible non-steroidal aromatase inhibitor for dissecting estrogen-dependent biology. This assay-centered guide connects its heme-iron binding chemistry with endpoint selection, endocrine interpretation, and synaptic research limitations.

• SR 11302: The Translational Case for AP-1 Blockade

  2026-08-08

  SR 11302 provides a research strategy for separating AP-1-driven tumor promotion from broader retinoid receptor activation. This thought-leadership perspective connects its cancer-cell and in vivo evidence with macrophage-polarization findings from a colitis-associated colorectal cancer study, while defining the controls needed for translational interpretation.

• BOP Reagent: Translational Leverage in Oncology

  2026-08-07

  A thought-leadership analysis of how BOP reagent supports disciplined peptide chemistry while informing translational strategy for carrier-free, ROS-responsive oncology platforms. The discussion connects carboxyl group activation and amide bond formation with the mechanistic lessons of a triterpene-based oral squamous cell carcinoma prodrug study.

• STT3B and N-Glycan Pathways Mediate α-Amanitin Cytotoxicity

  2026-08-07

  This study identifies STT3B, a key enzyme in N-glycan biosynthesis, as essential for α-amanitin toxicity using genome-wide CRISPR screening. The discovery that the FDA-approved dye indocyanine green inhibits STT3B and protects against α-amanitin toxicity advances both mechanistic understanding and therapeutic possibilities for amatoxin poisoning.

• HyperFusion High-Fidelity DNA Polymerase in Neurodegeneratio

  2026-08-06

  HyperFusion™ high-fidelity DNA polymerase accelerates and streamlines PCR workflows for neurodegeneration research, excelling in the amplification of GC-rich and complex templates. Its unmatched fidelity and inhibitor resistance enable robust, reproducible results from challenging samples, empowering advanced applications in cloning, genotyping, and high-throughput sequencing.

• Antiarrhythmic Drug Effects on Cardiac KCa2 Channels in AF R

  2026-08-06

  This study systematically investigates whether commonly used antiarrhythmic agents, including Dronedarone (Multaq), directly inhibit small conductance calcium-activated potassium (KCa2.X) channels—a promising atrial-selective target in atrial fibrillation (AF) therapy. The findings reveal that most clinically approved agents do not significantly inhibit KCa2 channels at therapeutic concentrations, highlighting a mechanistic gap and guiding future research toward more selective atrial targets.

• Cy3-dCTP for Direct Enzymatic DNA Labeling: Protocols & Insi

  2026-08-05

  Cy3-dCTP redefines direct enzymatic labeling of DNA and cDNA, offering exceptional fluorescence and compatibility with advanced workflows like Nick Translation and in situ hybridization. Learn how it integrates with 3D DNA frameworks to boost assay performance and discover troubleshooting strategies for optimal results.

• Rosiglitazone (Brl-49653): Driving Translational Advances in

  2026-08-05

  This article explores the mechanistic and translational landscape of Rosiglitazone (Brl-49653), a benchmark PPARγ agonist, in the context of adipose tissue remodeling, insulin sensitivity, and metabolic disease research. Integrating recent advances in SETD7-regulated WAT browning and leveraging APExBIO’s high-purity Rosiglitazone, we deliver protocol guidance and strategic insights for researchers aiming to bridge molecular mechanisms with next-generation therapeutic strategies for type II diabetes and obesity.

• I-BET-762: BET Inhibitor Workflows for Cancer and Inflammati

  2026-08-04

  I-BET-762, a selective BET inhibitor from APExBIO, enables robust modulation of transcriptional and epigenetic programs in both cancer biology and inflammatory disease models. This guide provides actionable, evidence-backed workflows, troubleshooting strategies, and a synthesis of the latest mechanistic breakthroughs—including the synergy of BRD4 inhibition and ferroptosis—for translational research.

450 records 8/30 page Previous Next First page 上5页 678910 下5页 Last page